Paper Details

  1. Home
  2. Paper Details

Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.

Author: , BenatorDebra A, BensonConstance A, CalvetGuilherme, ChaissonRichard E, ChenMichael P, GordinFred, InfanteRosa, La RosaAlberto, MiroJose M, ScottNigel A, SterlingTimothy R, VillarinoM Elsa

Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Weekly rifapentine and isoniazid under direct observation (3HP) was as effective and safe for treatment of latent Mycobacterium tuberculosis infection as 9 months of daily isoniazid (9H), and better tolerated.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: Compare the effectiveness, tolerability, and safety of 3 months of weekly rifapentine and isoniazid under direct observation (3HP) versus 9 months of daily isoniazid (9H) in HIV-infected persons. DESIGN: Prospective, randomized, and open-label noninferiority trial. SETTING: The United S...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/QAD.0000000000001098

データ提供：米国国立医学図書館（NLM）

Weekly Rifapentine and Isoniazid: A Shorter Treatment for Latent Tuberculosis Infection in HIV-Infected Individuals

Latent tuberculosis infection (LTBI), a silent threat lurking within the body, is like a hidden oasis in a vast desert, posing a risk of developing active tuberculosis. Finding effective treatments for LTBI, especially in individuals with HIV, is crucial. This study, like a caravan of researchers traversing a desert of medical challenges, investigates a new approach to treating LTBI in HIV-infected individuals. The researchers compared two treatment regimens: a shorter regimen involving weekly rifapentine and isoniazid for 3 months and a longer regimen involving daily isoniazid for 9 months.

Weekly Rifapentine and Isoniazid: A Shorter Treatment for Latent Tuberculosis Infection in HIV-Infected Individuals

The study concluded that the shorter treatment regimen, involving weekly rifapentine and isoniazid for 3 months, was as effective and safe as the longer regimen in treating LTBI in HIV-infected individuals.

Weekly Rifapentine and Isoniazid: A Shorter Treatment for Latent Tuberculosis Infection in HIV-Infected Individuals

This study presents a shorter, potentially more convenient and better-tolerated treatment option for LTBI in HIV-infected individuals.

Dr.Camel's Conclusion

This study demonstrates that a shorter treatment regimen involving weekly rifapentine and isoniazid is as effective and safe as the longer, daily isoniazid regimen for treating latent tuberculosis infection in HIV-infected individuals.
Date :
  1. Date Completed 2017-12-19
  2. Date Revised 2019-10-08
Further Info :

Pubmed ID

27243774

DOI: Digital Object Identifier

10.1097/QAD.0000000000001098

Related Literature

Article Analysis
・Side Effects of rifapentine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.